Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523945 | 1.00 | SLC7A5 (0.57) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL3476198 | 0.98 | SLC7A5 (0.56) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL168028 | 0.89 | SLC7A5 (0.59) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL25234890 | 0.86 | SLC7A5 (0.56) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL7155008 | 0.85 | ALPI (0.58) | SLC7A5HDAC8 | |
| SCHEMBL28872276 | 0.85 | ALPI (0.58) | SLC7A5HDAC8 | |
| SCHEMBL29969329 | 0.83 | SLC7A5 (0.53) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| Tyrosine Methyl Ester SCHEMBL28726421 | 0.83 | ESR1 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL27680265 | 0.81 | SLC7A5 (0.67) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL4453960 | 0.81 | SLC7A5 (0.67) | SLC7A5TAAR1HDAC8SLC6A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083469-A | Complex comprising both heparin binding proteins and heparin-hydroxyalkyl starch conjugates | OCTAPHARMA AG | 2011-06-01 | — | — | CN | claimed |
| US-20240117030-A1 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | PFIZER (US) | 2024-04-11 | — | — | US | disclosed |
| CN-117653725-A | anti-CCR 8 antibody therapy: biomarkers and combination therapies | 拜耳公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | Encodia, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023166418-A2 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | PFIZER INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166420-A1 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | PFIZER INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279417-A1 | ROOT-SECRETED PEPTIDE PEP1 IN RICE AND GENE ENCODING THE SAME AND USE THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230250178-A1 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-10 | — | — | US | disclosed |
| CN-114524871-B | Variant SH2 domains with high affinity for tyrosine-containing sulfated modified peptides | 青岛赛诺基因科技有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116234825-A | CCR8 antibodies for therapeutic applications | 拜耳公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-1997018315-A1 | HYBRID FACTOR VIII WITH MODIFIED ACTIVITY | IMMUNO AKTIENGESELLSCHAFT (AT) | 1997-05-22 | — | — | WO | disclosed |
| EP-0531537-B1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORP (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5552299-A | ANTICOAGULANT | BIOGAL GYOGYSZERGYAR RT. (HU) | 1996-09-03 | — | — | US | disclosed |
| US-5508437-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| CN-1113389-A | High molecular weight desulphatohirudin | CIBA GEIGY AG (CH) | 1995-12-13 | — | — | CN | disclosed |
| US-5296608-A | Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides | HOFFMAN-LA ROCHE INC. (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0576792-A2 | Plasmids and process for producing recombinant desulphatohirudin HV-1 peptide | BIOGAL GYOGYSZERGYAR RT. (HU) | 1994-01-05 | — | — | EP | disclosed |
| EP-0531537-A1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORPORATION (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-5182263-A | Appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0161468-A3 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF PEPTIDES WHICH CONTAIN SULFATED TYROSINE | PENNWALT CORPORATION (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | TNNI3, CHD1, TNNT2 | SLC7A5 501/4885TAAR1 1481/4885HDAC8 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.